UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 22, 2014
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | | 000-23143 | | 13-3379479 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | | |
| 777 Old Saw Mill River Road, Tarrytown, New York | | 10591 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant's telephone number, including area code (914) 789-2800 |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Progenics Pharmaceuticals, Inc. today presented positive data from a pivotal phase 2 clinical study of Azedra™ (Ultratrace™ Iobenguane I-131), the company's radio-therapeutic candidate for pheochromocytoma and paraganglioma. Lead investigator Daniel Pryma, M.D., Associate Professor of Radiology and Clinical Director of Nuclear Medicine and Molecular Imaging, Department of Radiology at the University of Pennsylvania, made the oral presentation at the International Symposium of Pheochromocytoma and Paraganglioma (ISP) in Kyoto, Japan.
A copy of the company's press release is included in this Report as Exhibit 99.1.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PROGENICS PHARMACEUTICALS, INC. |
| By: | /s/ ANGELO W. LOVALLO, JR. |
| | Angelo W. Lovallo, Jr. |
| | Vice President - Finance & Treasurer |
| | (Principal Financial and Accounting Officer) |
Date: September 22, 2014
